Q-omics provides the consensus-scored PPBP profile across patient tissues and cancer cell-line models. PPBP expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, PPBP is differentially expressed in 9, with the highest sampling consensus in LUSC. Additionally, PPBP protein abundance shows 16,148 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SCLC, LUSC, and GBM as cancer lineages where PPBP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPBP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPBP survival associations across molecular data types. PPBP RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPBP RNA expression–survival associations across cancer types. High PPBP expression shows unfavorable associations in SCLC, THCA, ACC, LAML, SARC and SKCM. The SCLC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify SCLC as the clearest survival context for PPBP RNA expression.
This table summarizes PPBP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 7. The strongest signals are observed in LUSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PPBP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPBP shows lower tumor expression in LUSC, LUAD, KICH and LIHC and higher tumor expression in COAD and HNSC. The LUSC box plot shows higher PPBP RNA expression in normal versus tumor tissue (log2 FC = −4.004, t-test p < 0.001).
This table shows molecular features associated with PPBP in patient tissues and cancer cell lines. In patient samples, PPBP shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PPBP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
